McKesson Corporation vs Americas Gold and Silver Corporation Common Shares no par value — how do they compare? McKesson Corporation trades at $974.82 (market cap $112.15B), while Americas Gold and Silver Corporation Common Shares no par value trades at $3.91 (market cap $1.36B). The key difference: McKesson Corporation is far larger — about 82.5× Americas Gold and Silver Corporation Common Shares no par value's market cap, and McKesson Corporation pays a 0.39% dividend while Americas Gold and Silver Corporation Common Shares no par value pays none. Which is the better fit depends on your goals — on Pluang, investors hold McKesson Corporation for 74 Days and Americas Gold and Silver Corporation Common Shares no par value for 0 Days on average.
| MCK | USAS | |
|---|---|---|
Market Cap | $112.15B | $1.36B |
Volume | 743,618 | 3,177,621 |
Sector | Health | Basic Materials |
52-Week High | $995.69 | $10.03 |
52-Week Low | $725.17 | $3.59 |
Typical Hold Time | 74 Days | 0 Days |
Enterprise Value | $118.68B | $1.29B |
Dividend Yield | 0.39% | — |
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $976.57, up 2.18% with strong technical momentum and bullish analyst sentiment. The stock shows robust earnings performance with three consecutive quarterly beats and revenue growth from $309B to $359B annually. Recent news highlights the CVS Health partnership extension through 2032, reinforcing distribution stability. Technical indicators show bullish moving averages but overbought RSI levels near resistance at $978.
Outlook remains positive given earnings momentum and strategic partnerships, though valuation at 25.8x P/E and thin 1.12% net margins pose risks. Analysts maintain 80.65% buy ratings with $956 consensus target, slightly below current price. Key risks include drug pricing pressure and macroeconomic sensitivity. Institutional accumulation supports medium-term upside if execution continues.
USAS trades at $4.02, down 4.29% on the day, reflecting ongoing volatility amid mixed operational performance. The company reported a net loss of $87.45M in 2025, though revenue is projected to grow to $182M in 2026 with a narrowing loss. Recent news highlights progress at its Galena and Cosalá mines, including high-grade silver discoveries and sustainability initiatives, signaling potential for future production growth.
The outlook is speculative, with high-risk turnaround potential driven by operational improvements and exposure to silver and critical minerals. Key risks include persistent negative profitability, high valuation multiples like EV/EBITDA of 455.68, and reliance on successful mine development. Analyst consensus is unanimously bullish, but investors must weigh execution risks against long-term growth prospects.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →Americas Gold and Silver Corporation is a Canada-based mining company that explores for and produces silver, along with by-product gold, copper, lead, and zinc. Its operating assets include the Galena Complex in Idaho and the Cosalá Operations in Sinaloa, Mexico.
Read more on USAS →